Vanguard Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,910,984
| Closed | -$11.2M | – | 4609 |
|
|
2022
Q4 | $11.2M | Buy |
1,910,984
+69,214
| +4% | +$364K | ﹤0.01% | 2906 |
|
|
2022
Q3 | $12.3M | Buy |
1,841,770
+252,572
| +16% | +$1.53M | ﹤0.01% | 2850 |
|
|
2022
Q2 | $6.69M | Buy |
1,589,198
+711,037
| +81% | +$2.81M | ﹤0.01% | 3213 |
|
|
2022
Q1 | $2.96M | Sell |
878,161
-336,455
| -28% | -$1.07M | ﹤0.01% | 3784 |
|
|
2021
Q4 | $3.83M | Sell |
1,214,616
-23,344
| -2% | -$77.7K | ﹤0.01% | 3761 |
|
|
2021
Q3 | $4.05M | Sell |
1,237,960
-56
| -0% | -$196 | ﹤0.01% | 3784 |
|
|
2021
Q2 | $5.22M | Sell |
1,238,016
-152,050
| -11% | -$644K | ﹤0.01% | 3579 |
|
|
2021
Q1 | $6.94M | Buy |
1,390,066
+93,565
| +7% | +$756K | ﹤0.01% | 3359 |
|
|
2020
Q4 | $16.4M | Buy |
1,296,501
+35,820
| +3% | +$408K | ﹤0.01% | 2735 |
|
|
2020
Q3 | $12.4M | Sell |
1,260,681
-9,077
| -0.7% | -$89.4K | ﹤0.01% | 2681 |
|
|
2020
Q2 | $12.6M | Buy |
1,269,758
+63,042
| +5% | +$605K | ﹤0.01% | 2647 |
|
|
2020
Q1 | $10.7M | Buy |
1,206,716
+160,122
| +15% | +$1.58M | ﹤0.01% | 2586 |
|
|
2019
Q4 | $9.65M | Sell |
1,046,594
-5,295
| -0.5% | -$37.5K | ﹤0.01% | 2874 |
|
|
2019
Q3 | $6.18M | Buy |
1,051,889
+43,894
| +4% | +$466K | ﹤0.01% | 3054 |
|
|
2019
Q2 | $12.1M | Buy |
1,007,995
+49,502
| +5% | +$532K | ﹤0.01% | 2745 |
|
|
2019
Q1 | $11.6M | Sell |
958,493
-25,753
| -3% | -$380K | ﹤0.01% | 2750 |
|
|
2018
Q4 | $12.4M | Sell |
984,246
-241,603
| -20% | -$3.34M | ﹤0.01% | 2667 |
|
|
2018
Q3 | $18.2M | Buy |
1,225,849
+91,659
| +8% | +$1.44M | ﹤0.01% | 2626 |
|
|
2018
Q2 | $19.1M | Buy |
1,134,190
+55,413
| +5% | +$1.08M | ﹤0.01% | 2584 |
|
|
2018
Q1 | $24.7M | Buy |
1,078,777
+302,402
| +39% | +$6.73M | ﹤0.01% | 2415 |
|
|
2017
Q4 | $20.1M | Buy |
776,375
+34,697
| +5% | +$699K | ﹤0.01% | 2488 |
|
|
2017
Q3 | $10.9M | Sell |
741,678
-14,835
| -2% | -$215K | ﹤0.01% | 2766 |
|
|
2017
Q2 | $10.6M | Buy |
756,513
+74,801
| +11% | +$1.1M | ﹤0.01% | 2743 |
|
|
2017
Q1 | $11.6M | Buy |
681,712
+38,892
| +6% | +$466K | ﹤0.01% | 2695 |
|
|
2016
Q4 | $6.62M | Buy |
642,820
+16,562
| +3% | +$151K | ﹤0.01% | 2934 |
|
|
2016
Q3 | $6.33M | Buy |
626,258
+19,899
| +3% | +$217K | ﹤0.01% | 2889 |
|
|
2016
Q2 | $6.81M | Buy |
606,359
+23,885
| +4% | +$304K | ﹤0.01% | 2828 |
|
|
2016
Q1 | $7.96M | Buy |
582,474
+47,205
| +9% | +$679K | ﹤0.01% | 2732 |
|
|
2015
Q4 | $10.2M | Buy |
535,269
+13,581
| +3% | +$295K | ﹤0.01% | 2629 |
|
|
2015
Q3 | $9.79M | Buy |
521,688
+98,450
| +23% | +$1.67M | ﹤0.01% | 2615 |
|
|
2015
Q2 | $6.3M | Buy |
423,238
+56,375
| +15% | +$859K | ﹤0.01% | 2900 |
|
|
2015
Q1 | $5.55M | Buy |
366,863
+16,000
| +5% | +$223K | ﹤0.01% | 2943 |
|
|
2014
Q4 | $4.67M | Sell |
350,863
-56,349
| -14% | -$728K | ﹤0.01% | 2933 |
|
|
2014
Q3 | $5.13M | Buy |
407,212
+328,478
| +417% | +$3.19M | ﹤0.01% | 2815 |
|
|
2014
Q2 | $796K | Buy |
78,734
+44,051
| +127% | +$425K | ﹤0.01% | 3546 |
|
|
2014
Q1 | $467K | Buy |
+34,683
| New | +$490K | ﹤0.01% | 3667 |
|
Vanguard Group's CNCE Position: Q1 2023 in Review
Vanguard Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,910,984 shares — an estimated $11.2M sold.
Vanguard Group first reported a position in CNCE in Q1 2014 and held it in 36 quarters. The position peaked at $24.7M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Vanguard Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Vanguard Group sold 1,910,984 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.2M.
- Vanguard Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Vanguard Group's Concert Pharmaceuticals, Inc. position peaked at $24.7M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.